Medicare Part D: The New US Voluntary Prescription Drug Benefit
This article was originally published in SRA
Karen Finn describes the largest reform to the Medicare programme since its inception and discusses how it may affect the various stakeholders.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.